Familial Cancer

Scope & Guideline

Fostering breakthroughs in hereditary cancer understanding.

Introduction

Immerse yourself in the scholarly insights of Familial Cancer with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN1389-9600
PublisherSPRINGER
Support Open AccessNo
CountryNetherlands
TypeJournal
Converge2001, from 2003 to 2024
AbbreviationFAM CANCER / Fam. Cancer
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressVAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS

Aims and Scopes

The journal 'Familial Cancer' focuses on the intersection of genetics and oncology, emphasizing inherited cancer syndromes and their implications for screening, diagnosis, and management. It aims to enhance understanding of familial cancer predispositions while promoting innovative research methodologies.
  1. Genetic predisposition to cancer:
    The journal emphasizes research on hereditary cancer syndromes, including the identification and characterization of genetic variants associated with increased cancer risk.
  2. Screening and surveillance strategies:
    A core area of focus is the development and evaluation of screening protocols for high-risk individuals, particularly those with familial cancer syndromes like Lynch syndrome and hereditary breast and ovarian cancer.
  3. Clinical management and interventions:
    The journal addresses clinical strategies for the management of hereditary cancers, including risk-reducing surgeries, chemoprevention, and personalized treatment approaches based on genetic profiles.
  4. Psychosocial aspects of genetic testing:
    Research on the psychological impact of genetic testing and the experiences of patients and families navigating hereditary cancer risk is an important theme, highlighting the need for supportive care.
  5. Policy and healthcare delivery:
    The journal also explores healthcare policy implications and the integration of genetic testing into clinical practice, focusing on improving access and equity in cancer care.
The landscape of research published in 'Familial Cancer' shows a dynamic evolution, with several themes emerging in recent years that reflect current challenges and advancements in the field.
  1. Integration of genomic technologies:
    Recent studies increasingly utilize advanced genomic techniques, such as whole genome sequencing and multi-gene panels, to identify hereditary cancer syndromes and characterize variants, reflecting the growing importance of precision medicine.
  2. Cascade testing and family communication:
    There is a rising emphasis on cascade genetic testing and the psychosocial dynamics of communicating genetic risk within families, highlighting the importance of family involvement in hereditary cancer management.
  3. Health disparities and access to care:
    Emerging themes include the examination of health disparities in access to genetic testing and cancer care, particularly among underrepresented populations, which is critical for equitable healthcare delivery.
  4. Long-term outcomes and survivorship:
    Studies focusing on long-term outcomes for individuals with hereditary cancer syndromes, including survivorship issues and quality of life, are becoming more prominent, addressing the holistic needs of patients post-diagnosis.
  5. Digital health innovations:
    The integration of digital health tools for cancer risk assessment and genetic counseling is a trending area of research, reflecting a shift towards technology-driven solutions in healthcare.

Declining or Waning

While the journal continues to explore a wide range of topics related to familial cancer, certain areas appear to be less frequently addressed in recent publications, indicating a potential decline in focus.
  1. Non-genetic factors in cancer risk:
    There has been a noticeable decrease in studies focusing on environmental or lifestyle factors contributing to familial cancer risk, suggesting a shift towards more genetic and molecular investigations.
  2. Rare cancer syndromes:
    Research on less common hereditary cancer syndromes, while still relevant, has seen a decline in frequency, as the journal's focus has increasingly gravitated towards more prevalent syndromes like Lynch syndrome and BRCA-related cancers.
  3. General population studies:
    The journal appears to be moving away from large-scale studies of general populations in favor of targeted research in specific high-risk groups, potentially reducing the breadth of its epidemiological coverage.

Similar Journals

CANCER CAUSES & CONTROL

Advancing Insights into Cancer Causes and Prevention
Publisher: SPRINGERISSN: 0957-5243Frequency: 12 issues/year

Cancer Causes & Control, an esteemed journal within the field of Cancer Research and Oncology, is published by SPRINGER. Since its inception in 1990, this journal has dedicated itself to exploring the complex interplay between environmental, genetic, and lifestyle factors that contribute to cancer causation and control, aiming to inform public health initiatives and improve cancer prevention strategies. With an impressive Q2 rank in both its categories, the journal serves as a vital resource for researchers, professionals, and students seeking insights into the latest findings and methodologies in cancer epidemiology. Although there is no Open Access option, researchers can access valuable articles that reflect rigorous peer review and significant contributions to the field. The journal’s commitment to advancing knowledge related to cancer risks and management makes it an essential platform for disseminating impactful research and fostering collaboration among scholars worldwide.

BULLETIN DU CANCER

Exploring the frontiers of oncology research.
Publisher: ELSEVIER MASSON, CORP OFFISSN: 0007-4551Frequency: 12 issues/year

BULLETIN DU CANCER is a pivotal academic journal dedicated to the field of oncology, providing a platform for innovative research and insights into cancer treatment and diagnostics. Published by Elsevier Masson, Corp Off in France, this journal has been a part of the scientific community since 1966, and is committed to sharing critical findings that influence clinical practices and improve patient outcomes. Despite its recent rankings placing it in the Q4 category for Cancer Research and Q3 for Hematology and other related fields, BULLETIN DU CANCER remains essential for those interested in the latest developments in cancer biology and treatment methodologies. With an emphasis on both basic and clinical research, it serves as a valuable resource for researchers, healthcare professionals, and students seeking to deepen their understanding in various dimensions of oncology. This journal is particularly relevant as it continues to spotlight emerging research trends and supports the global imperative to combat cancer more effectively.

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Advancing Insights in Hematology and Oncology
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 0889-8588Frequency: 6 issues/year

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, published by W B SAUNDERS CO-ELSEVIER INC, is a premier journal dedicated to advancing the fields of hematology and oncology. With its ISSN 0889-8588 and E-ISSN 1558-1977, this esteemed publication has been a cornerstone of clinical scholarship since its inception in 1987, providing comprehensive annual updates that bridge the gap between research and clinical practice. Known for its rigorous editorial standards and impactful contributions, the journal holds a respectable Q2 quartile classification in both hematology and oncology as of 2023, ranking it in the 50th percentile among its peers. Although it is not an open-access journal, the content is accessible to institutions and professionals worldwide. As the scope of the journal expands through 2024, it continues to attract an audience of researchers, healthcare professionals, and students who seek to stay informed on the latest advancements, treatment modalities, and groundbreaking studies in the fields of hematology and oncology.

Journal of the Egyptian National Cancer Institute

Innovating cancer care with groundbreaking research.
Publisher: SPRINGERISSN: 1110-0362Frequency: 1 issue/year

Journal of the Egyptian National Cancer Institute, published by SPRINGER, serves as a vital platform for disseminating innovative research in the field of oncology and cancer research. With both ISSN 1110-0362 and E-ISSN 2589-0409, this Open Access journal has been committed to making significant contributions to the scientific community since its inception in 2005. Operating from its base in Egypt, it has established itself as an important resource for researchers, practitioners, and students alike, offering insights into contemporary issues and advancements in cancer care. Recognized in the 2023 category quartiles as Q3 in Cancer Research and Q3 in Oncology, the journal is positioned to impact the ongoing discourse in cancer treatment strategies and health policy. As it continues to publish peer-reviewed articles through available Open Access avenues, the Journal of the Egyptian National Cancer Institute remains dedicated to enhancing the knowledge base and collaborative efforts within the global cancer research community.

Frontiers in Oncology

Empowering breakthroughs in cancer treatment and care.
Publisher: FRONTIERS MEDIA SAISSN: 2234-943XFrequency: 1 issue/year

Frontiers in Oncology is a premier open access journal dedicated to advancing the field of oncology through innovative research and knowledge dissemination. Published by FRONTIERS MEDIA SA since 2011, this journal is based in Switzerland and holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, highlighting its significance in the academic community. With its commitment to open access, Frontiers in Oncology ensures that vital research is readily available to researchers, healthcare professionals, and students around the globe, enhancing collaboration and fostering breakthroughs in cancer research. The journal's robust Scopus rankings further illustrate its academic influence, with notable positions in the fields of Oncology and Cancer Research. By covering a wide range of topics within oncology, this journal serves as a vital resource, supporting the rapid evolution of cancer treatment, diagnostics, and patient care strategies.

Journal of Cancer Policy

Shaping the future of oncology with strategic insights.
Publisher: ELSEVIER SCI LTDISSN: Frequency: 4 issues/year

Journal of Cancer Policy is an esteemed publication devoted to the critical intersection of health policy and oncology. Published by Elsevier Sci Ltd in the United Kingdom, this journal has been a pivotal platform since its inception in 2013, contributing to the field's discourse on cancer management and policy-making strategies. With an impressive Q2 ranking in both the Health Policy and Oncology categories for 2023, it underscores its significance in shaping policy frameworks that address the complexities of cancer care. The journal is listed in Scopus with a respectable rank of #177 in Health Policy and #261 in Oncology, indicating its broad reach and impactful contributions to research and scholarly discussions. While the journal operates under a subscription model, it aims to provide readers with high-quality research that can influence health decisions and policy formation. As a vital resource for researchers, healthcare professionals, and students alike, the Journal of Cancer Policy plays a fundamental role in advancing the understanding of how policies can improve cancer outcomes and healthcare systems.

Current Problems in Cancer: Case Reports

Advancing oncology through shared case insights.
Publisher: ELSEVIERISSN: 2666-6219Frequency: 2 issues/year

Current Problems in Cancer: Case Reports is a prominent scholarly journal published by Elsevier, focusing on critical case reports within the field of oncology. Since its transition to Open Access in 2020, it has enhanced accessibility for researchers and healthcare professionals seeking to share and discuss unique clinical scenarios and insights that advance cancer treatment and patient care. Operating from the United States, this journal aims to address the important and often intricate challenges faced in oncology, facilitating a platform for knowledge exchange and the exploration of new perspectives in cancer management. Despite its current Q4 category ranking in the 2023 oncology category of Scopus with a rank of #359/404, its goal is to enrich the academic discourse by featuring diverse case reports and promoting evidence-based practices. As the journal evolves from 2021 to 2024, it seeks to impact the field by inviting researchers, professionals, and students to contribute their findings, ultimately fostering a collaborative environment for tackling the complexities of cancer.

Turk Onkoloji Dergisi-Turkish Journal of Oncology

Shaping the future of oncology with dedicated research and expertise.
Publisher: KARE PUBLISSN: 1300-7467Frequency: 4 issues/year

Turk Onkoloji Dergisi - Turkish Journal of Oncology, published by KARE PUBL, serves as a vital platform in the field of oncology, specifically catering to the Turkish-speaking research community and contributing to global discourse. With an ISSN of 1300-7467, this journal, which has been in circulation since 2007 and continues until 2024, recognizes the importance of advancing medical knowledge in cancer research through rigorous peer-reviewed articles. Although currently positioned in the Q4 category of oncology journals with a Scopus rank of #344 out of 404, the journal is dedicated to fostering significant research insights and innovative perspectives on cancer treatment and prevention. While it does not currently offer open access, its content is essential for professionals, researchers, and students aiming to enhance their understanding of oncology developments in Turkey and beyond. The Turkish Journal of Oncology not only aspires to improve the quality of cancer care but also strives to enhance collaboration among researchers, thereby influencing future oncology practices.

World Journal of Gastrointestinal Oncology

Connecting research and practice in gastrointestinal health and cancer.
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 1948-5204Frequency: 12 issues/year

World Journal of Gastrointestinal Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a pivotal resource in the evolving fields of gastroenterology and oncology, particularly focused on the intricate relationship between gastrointestinal disorders and cancer. Established in 2014, the journal continues to publish influential research, boasting a commendable Q2 ranking in both the gastroenterology and oncology categories for 2023, which underscores its importance in these critical medical domains. With a diverse range of topics and studies, it serves as an essential platform for researchers, healthcare professionals, and students aiming to stay informed about the latest advancements and innovations in gastrointestinal oncology. Though currently not classified as open access, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to clinical practice and patient care. Its positioning in the Scopus rankings also highlights its competitive standing within the scientific community, fostering discussions that are crucial for advancing both fields. Explore the latest insights and findings to enhance your understanding and contribute to the ongoing dialogue in gastrointestinal health and oncology.

CURRENT PROBLEMS IN CANCER

Transforming Knowledge: Navigating Contemporary Challenges in Oncology
Publisher: MOSBY-ELSEVIERISSN: 0147-0272Frequency: 6 issues/year

CURRENT PROBLEMS IN CANCER is an esteemed journal published by MOSBY-ELSEVIER, dedicated to advancing the field of oncology and cancer research. With an ISSN of 0147-0272 and an E-ISSN of 1535-6345, it has been a vital resource for over four decades, converging years of expertise from 1976 to 2024. The journal is recognized for its impactful contribution to the field, currently holding a Q3 ranking in Cancer Research and a Q2 ranking in Oncology, reflecting its importance in disseminating significant advancements and discussions in the field. It is ranked #164 out of 404 in Medicine _ Oncology and #131 out of 230 in Biochemistry, Genetics and Molecular Biology _ Cancer Research on Scopus, indicating its relevance and reach among academic circles. Although it does not offer open access, the journal remains a crucial platform for researchers and professionals seeking to explore contemporary issues in cancer treatment and management. With its commitment to quality and innovation, CURRENT PROBLEMS IN CANCER serves as an essential conduit for knowledge sharing and research development in oncology and cancer science.